All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (liver )
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Extensive stage SCLC (Es-SCLC) - maintenance (M), nivolumab plus ipilimumab vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 451 (NI ; all population), 2019 0.92 [0.75; 1.12]
0.92 [0.75 ; 1.12 ] CheckMate 451 (NI ; all population), 2019 1 0% 554 NA not evaluable progression or deaths (PFS)detailed results CheckMate 451 (NI ; all population), 2019 0.72 [0.60; 0.87]
0.72 [0.60 ; 0.87 ] CheckMate 451 (NI ; all population), 2019 1 0% 554 NA not evaluable objective responses (ORR)detailed results CheckMate 451 (NI ; all population), 2019 2.33 [1.11; 4.90]
2.33 [1.11 ; 4.90 ] CheckMate 451 (NI ; all population), 2019 1 0% 554 NA not evaluable TRAE (any grade)detailed results CheckMate 451 (NI ; all population), 2019 4.23 [2.89; 6.20]
4.23 [2.89 ; 6.20 ] CheckMate 451 (NI ; all population), 2019 1 0% 554 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 451 (NI ; all population), 2019 12.44 [7.59; 20.41]
12.44 [7.59 ; 20.41 ] CheckMate 451 (NI ; all population), 2019 1 0% 554 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 451 (NI ; all population), 2019 7.05 [0.86; 57.70]
7.05 [0.86 ; 57.70 ] CheckMate 451 (NI ; all population), 2019 1 0% 554 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 451 (NI ; all population), 2019 60.82 [14.79; 250.13]
60.82 [14.79 ; 250.13 ] CheckMate 451 (NI ; all population), 2019 1 0% 554 NA not evaluable 0.5 100.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-11 09:37 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 194
- treatments: 416,864
